Delhi HC lets Dr Reddy's make and export key diabetes drug (but not sell it in India yet)
The Delhi High Court just gave Dr Reddy's Laboratories the green light to keep making and exporting semaglutide—the main ingredient in popular diabetes and weight-loss meds—despite a patent fight with Novo Nordisk.
There's a catch: DRL still can't sell the drug in India until Novo's patent runs out in March next year.
Why does this matter?
The court sided with DRL, saying their challenge to Novo's patent actually holds up.
It also called out Novo for trying to "evergreen" its rights by filing overlapping patents.
The court characterized this as evergreening, which is prohibited under Indian patent law.
Thanks to this decision, DRL can now send semaglutide to countries like Canada, Brazil, China, and Turkey once local patents expire, which could mean more affordable treatment options for people dealing with diabetes or obesity worldwide.
This ruling also puts pressure on big pharma pricing.